Review of the evidence base of representatives of the group of sodium-glucose co-transporter 2 inhibitors available at the Ukrainian market (literature review)

Review of the evidence base of representatives of the group of sodium-glucose co-transporter 2 inhibitors available at the Ukrainian market (literature review)

The article presents an analysis of the results of randomized clinical studies of glucose lowering drugs from the class of sodium-glucose transport protein 2 inhibitors in patients with type 2 diabetes: EMPA-REG OUTCOME® with empagliflozin and DECLARE-TIMI 58® with dapagliflozin. It is shown how the...

Full description

Bibliographic Details
Main Author: K.O. Zuiev
Format: Article
Language:English
Published: Publishing House Zaslavsky 2020-04-01
Series:Mìžnarodnij Endokrinologìčnij Žurnal
Subjects:
empagliflozin
dapagliflozin
sodium-glucose transport protein 2 inhibitors
type 2 diabetes
review
Online Access:http://iej.zaslavsky.com.ua/article/view/205273

Internet

http://iej.zaslavsky.com.ua/article/view/205273

Similar Items